Publication details
Panitumumab v 1. linii léčby metastatického kolorektálního karcinomu – výsledky v běžné praxi lepší než v registrační studii
| Title in English | Panitumumab in the first line treatment of metastatic colorectal cancer – results in routine practice better than in the registration study |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | metastatic colorectal cancer |
| Description | The prognosis of patients with metastatic colorectal cancer remains serious. First line treatment with anti-EGFR antibodies provides an opportunity to cure some patients if metastases resectability is achieved. The same regimen can delay disease progression; achieve symptom relief and prolong patient survival. First line regimen FOLFOX + panitumumab used in routine practice in Czech Republic provides better results in comparison with phase III clinical trial PRIME according to the CORECT registry results. Benefit of the treatment is limited to patients without RAS mutations. |